Bridgebio Pharma (BBIO)
NASDAQ:BBIO
Want to see BBIO full AI Analyst Report?
Top Page
BridgeBio Pharma
(NASDAQ:BBIO)
Select Model
Select Model
Rating:53Neutral
Price Target:
$67.00
▼(-12.70% Downside)
Action:Reiterated
Date:05/14/26
The score is held back primarily by weak financial performance (large losses, heavy cash burn, and negative equity) and bearish technicals (negative MACD and price below key moving averages). Offsetting these are a strong and improving commercial narrative from the earnings call (rapid Atruvio growth, large cash balance, and breakeven/cash-flow positivity targets) plus incremental upside from recent NDA filings, while valuation signals are limited due to the negative P/E and no dividend.
Positive Factors
Commercial traction — Atruvio
Sustained, rapid Atruvio growth reflects durable commercial product-market fit in ATTR cardiomyopathy. Large, repeatable prescription volumes and growing frontline share suggest a scalable sales model and predictable revenue base that should support funding of pipeline launches and reduce reliance on milestone timing.
Negative Factors
Persistent cash burn and negative FCF
Sustained negative operating and free cash flow implies continued dependence on external financing to fund R&D and launches. Over several quarters this raises dilution and refinancing risk, limiting strategic flexibility and increasing the cost of capital for future trials or commercial expansion if cash generation does not quickly flip positive.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial traction — Atruvio
Sustained, rapid Atruvio growth reflects durable commercial product-market fit in ATTR cardiomyopathy. Large, repeatable prescription volumes and growing frontline share suggest a scalable sales model and predictable revenue base that should support funding of pipeline launches and reduce reliance on milestone timing.
Read all positive factors
BridgeBio Pharma Key Performance Indicators (KPIs)
Any
Revenue by Segment
Highlights how much revenue each business segment generates, providing insight into which areas are driving growth and which may need strategic adjustments.
Highlights how much revenue each business segment generates, providing insight into which areas are driving growth and which may need strategic adjustments.
Data provided by:
The Fly
The FlyBridgeBio Pharma (BBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.54B
Dividend YieldN/A
Average Volume (3M)2.82M
Price to Earnings (P/E)―
Beta (1Y)0.69
Revenue Growth355.17%
EPS Growth-6.09%
CountryUS
Employees725
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.75
Shares Outstanding195,861,240
10 Day Avg. Volume3,026,240
30 Day Avg. Volume2,824,691
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)-7.27
Price to Sales (P/S)30.05
P/FCF Ratio-33.75
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue27.66
Enterprise Value/Gross Profit29.50
Enterprise Value/Ebitda-26.69
Forecast
1Y Price Target
$107.41Price Target Upside39.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)-2.17
Revenue Forecast (FY)$955.51M
BridgeBio Pharma Business Overview & Revenue Model
Company Description
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage ...
How the Company Makes Money
BridgeBio makes money primarily through (1) product revenue from commercialized therapies and (2) collaboration, licensing, and related payments tied to its pipeline.
1) Product revenue: When BridgeBio has an approved product on the market, it ge...
BridgeBio Pharma Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Positive
The call conveyed strong commercial momentum (notably Atruvio revenue growth: $180.6M, +24% QoQ, +392% YoY), robust cash runway ($940.2M) and clear pipeline progress with active launch preparations (LGMD2I NDA, ADH1 patient ID, positive PROPEL‑3 for achondroplasia). Management emphasized clinical differentiation backed by real‑world evidence and favorable long‑term economics, while acknowledging short‑term expense pressures (operating expenses +$72.1M) and an operating loss of $106M that should narrow later in the year. Competitive risks, diagnostic supply issues, and the prior‑year milestone timing created some near‑term revenue volatility, but overall the company presented multiple tangible positives that outweigh the listed challenges.Positive Updates
Atruvio Net Product Revenue Surge
Atruvio U.S. net product revenue of $180.6 million in Q1 2026, representing 24% quarter‑over‑quarter growth and 392% year‑over‑year growth; company describes brand as becoming a 2026 blockbuster with growing frontline share and >6,100 total new patient starts in the category this quarter.
Negative Updates
Sharp Decline in License & Services Revenue
License and services revenue fell to $0.4 million from $79.7 million year‑over‑year, reflecting the absence of a one‑time $75 million regulatory milestone recognized in the prior year; causes a revenue mix swing and volatility in reported top line.
Read all updates
Q1-2026 Updates
Positive
Negative
Atruvio Net Product Revenue Surge
Atruvio U.S. net product revenue of $180.6 million in Q1 2026, representing 24% quarter‑over‑quarter growth and 392% year‑over‑year growth; company describes brand as becoming a 2026 blockbuster with growing frontline share and >6,100 total new patient starts in the category this quarter.
Read all positive updates
Company Guidance
Management’s guidance emphasized continued Atruvio-driven growth and improving financial durability: Q1 total revenue was $194.5M (vs. $116.6M YoY) led by Atruvio U.S. net product revenue of $180.6M (24% q/q, +392% YoY), a $143.9M Atruvio lift that contributed to a $77.9M revenue increase overall; royalty revenue rose to $9.5M while license/services fell to $0.4M (prior-year $79.7M). They reported total operating expenses of $290.5M (SG&A $163.9M, +$57.5M; R&D $126.6M, +$15.2M), a $106M operating loss (but losses have narrowed >50% over five quarters), and $940.2M in cash and marketable securities (up from $587.5M), with guidance that losses should flatten over the next two quarters and the company expects to reach P&L breakeven and then sustainable cash-flow positivity by year‑end; the board also authorized a $500M share‑repurchase program to start immediately. Operational and pipeline metrics cited to support commercial outlook included >6,100 new patient starts in the ATTR class this quarter, a projected $4B peak for Atruvio, an IP runway of at least six years, real‑world signals such as a 43% reduction in diuretic intensification vs. tafamidis and Phase III OLE month‑54 mortality reductions (all‑cause −45%, CV −49%, p<0.0001), ~500 genetically confirmed LGMD2I U.S. patients, ~2,000 ADH1 patients identifiable via claims, achondroplasia unaided awareness >40%, and infigratinib’s 2.1 cm annualized height‑velocity benefit.BridgeBio Pharma Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 579.96M | 502.08M | 221.90M | 9.30M | 77.65M | 69.72M |
| Gross Profit | 543.90M | 473.81M | 218.02M | 6.86M | 74.21M | 66.60M |
| EBITDA | -601.06M | -672.88M | -436.83M | -565.47M | -397.44M | -533.83M |
| Net Income | -725.93M | -729.31M | -535.76M | -643.20M | -481.18M | -562.54M |
Balance Sheet | ||||||
| Total Assets | 1.37B | 936.02M | 919.34M | 546.38M | 623.04M | 1.01B |
| Cash, Cash Equivalents and Short-Term Investments | 940.19M | 587.48M | 681.10M | 434.88M | 471.92M | 836.66M |
| Total Debt | 3.38B | 2.73B | 1.73B | 1.74B | 1.72B | 1.73B |
| Total Liabilities | 3.64B | 3.01B | 2.38B | 1.89B | 1.87B | 1.88B |
| Stockholders Equity | -2.27B | -2.08B | -1.47B | -1.35B | -1.25B | -870.41M |
Cash Flow | ||||||
| Free Cash Flow | -454.12M | -447.01M | -521.66M | -529.03M | -425.81M | -546.18M |
| Operating Cash Flow | -443.95M | -445.91M | -520.73M | -527.72M | -419.49M | -497.93M |
| Investing Cash Flow | -65.03M | -24.49M | 60.78M | 54.03M | 453.15M | -200.83M |
| Financing Cash Flow | 848.26M | 359.29M | 748.46M | 451.54M | -13.13M | 736.45M |
BridgeBio Pharma Technical Analysis
Positive
76.75
Price Trends
71.23
Negative
72.19
Negative
65.98
Positive
Market Momentum
-1.08
Negative
49.27
Neutral
75.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BBIO, the sentiment is Positive. The current price of 76.75 is above the 20-day moving average (MA) of 68.48, above the 50-day MA of 71.23, and above the 200-day MA of 65.98, indicating a neutral trend. The MACD of -1.08 indicates Negative momentum. The RSI at 49.27 is Neutral, neither overbought nor oversold. The STOCH value of 75.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BBIO.
BridgeBio Pharma Risk Analysis
BridgeBio Pharma disclosed 101 risk factors in its most recent earnings report. BridgeBio Pharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BridgeBio Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
86 Outperform | $12.61B | 13.46 | 40.21% | ― | 3.33% | 38.64% | |
70 Outperform | $10.45B | 25.76 | 4.41% | ― | 12.53% | -49.09% | |
53 Neutral | $13.54B | -22.04 | 36.00% | ― | 355.17% | -6.09% | |
53 Neutral | $18.60B | -3.74 | -36.73% | ― | -29.97% | 6.60% | |
52 Neutral | $12.49B | -33.45 | -58.57% | ― | 47.40% | 32.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $11.93B | -40.25 | -50.15% | ― | 256.82% | 29.06% |
* Healthcare Sector Average
BBIO
BridgeBio Pharma
69.12
35.78
107.32%
BMRN
BioMarin Pharmaceutical
54.09
-3.46
-6.01%
EXEL
Exelixis
50.15
7.76
18.31%
IONS
Ionis Pharmaceuticals
75.56
42.58
129.11%
MDGL
Madrigal Pharmaceuticals
517.26
249.70
93.32%
MRNA
Moderna
46.88
20.62
78.52%
BridgeBio Pharma Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
BridgeBio Files FDA NDA for Encaleret in ADH1
Positive
May 13, 2026
On May 12, 2026, BridgeBio Pharma announced it had submitted a New Drug Application to the U.S. Food and Drug Administration for encaleret as a targeted treatment for autosomal dominant hypocalcemia type 1, following positive Phase 3 CALIBRATE res...
Private Placements and FinancingRegulatory Filings and Compliance
BridgeBio Pharma Launches New $500 Million ATM Program
Neutral
May 8, 2026
On May 7, 2026, BridgeBio Pharma, Inc. filed an automatic shelf registration statement on Form S-3ASR with the U.S. Securities and Exchange Commission and entered into a new Equity Distribution Agreement with Goldman Sachs Co. LLC and Leerink Par...
Business Operations and StrategyStock BuybackFinancial Disclosures
BridgeBio Pharma Announces $500 Million Stock Repurchase Program
Positive
May 7, 2026
BridgeBio reported first-quarter 2026 revenue of $194.5 million, largely driven by $180.6 million in U.S. Attruby sales, alongside expanding real-world evidence showing significant mortality and quality-of-life benefits versus existing therapies, ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
BridgeBio Files NDA for LGMD2I/R9 Oral Therapy
Positive
Mar 30, 2026
On March 30, 2026, BridgeBio Pharma announced that it had submitted a New Drug Application to the FDA for its oral therapy BBP-418 to treat limb-girdle muscular dystrophy type 2I/R9, a severe, progressive neuromuscular disease caused by FKRP gene ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.